2m 2m 2m 2m 2m 2m 2m
- $6.4BMarket Cap
- -30.38%1-Year Change
- Medical Instruments & SuppliesIndustry
AVANTOR (AVTR)
Key Performance
More- Earnings Score: 37
- Momentum Score: 31
- True Yield: N/A
- Financial Health Score: 6
Latest Research & News
The Iran-Israel conflict and potential Strait of Hormuz disruption are creating supply chain pressures on medical supplies through petrochemical derivatives. Key inputs like naphtha and methanol used in pharmaceutical packaging and drug synthesis are experiencing price increases. While hospitals haven't yet felt the impact, analysts expect cost pressures on IV bags, tubing, and other critical consumables to surface within 2-4 weeks as the disruption ripples through supply chains.
03/25/2026, 8:01 AM • Benzinga
Looking For A Rebound? China Tech and Emerging Markets Top Oversold List
Multiple China-focused stocks and emerging market ETFs have fallen into deeply oversold territory with exceptionally low RSI readings, potentially setting up for sharp rebounds if risk sentiment improves. The oversold list is dominated by Chinese internet and tech names alongside broader Asian and emerging market exposures, though investors are cautioned that low RSI alone is not a reliable trading signal.
03/04/2026, 12:41 PM • Benzinga
Avantor Stock Down 46% This Past Year, but One Fund's $23 Million Bet Signals Turnaround Potential
Despite Avantor's stock declining 46% over the past year, Chicago-based Kinney Asset Management increased its position to 1.85 million shares worth $23.03 million, making it the fund's largest holding. The move signals confidence in the company's turnaround potential, as management authorizes a $500 million share repurchase program while the company navigates a reset with softer biopharma demand and a $785 million goodwill impairment.
01/02/2026, 1:20 PM • The Motley Fool
Portnoy Law Firm Announces Class Action on Behalf of Avantor, Inc. Investors
Avantor, Inc. faces a class action lawsuit alleging that company executives failed to disclose weakening competitive positioning and increased competitive intensity affecting its Laboratory Solutions business. The company cut guidance multiple times in 2025 after reporting weak organic sales growth. Stock prices fell significantly following each earnings announcement (16%, 15%, and 23% declines), with the third quarter results revealing that actual performance was worse than management's recent projections.
12/29/2025, 9:45 AM • GlobeNewswire
Levi & Korsinsky, LLP has filed class action securities lawsuits against Avantor, Inc. (AVTR), Coupang, Inc. (CPNG), and DeFi Technologies (DEFT) alleging securities fraud. Avantor investors claim the company made false statements about its competitive positioning and concealed negative effects from increased competition during March 5, 2024 to October 28, 2025. Investors who suffered losses during the relevant periods can join the lawsuits at no cost.
12/26/2025, 4:56 PM • GlobeNewswire
The Schall Law Firm is seeking investors who purchased Avantor, Inc. securities between March 5, 2024, and October 28, 2025, for a class action lawsuit alleging securities fraud. The firm claims Avantor made false and misleading statements about its competitive position and struggled with increased competition, causing investor losses when the truth emerged.
12/26/2025, 9:10 AM • GlobeNewswire
Law firm alerts shareholders about potential securities fraud class action lawsuits for multiple companies, highlighting alleged misleading statements and financial misrepresentations during specific time periods.
12/18/2025, 12:00 PM • GlobeNewswire
Portnoy Law Firm Announces Class Action on Behalf of Avantor, Inc. Investors
Portnoy Law Firm announces a class action lawsuit against Avantor for allegedly misleading investors about competitive challenges in its Laboratory Solutions business, with stock prices declining after multiple financial result announcements revealing weak performance.
12/16/2025, 9:00 AM • GlobeNewswire
Rosen Law Firm alerts Avantor investors about a securities class action lawsuit regarding potential misrepresentations about the company's competitive positioning and business prospects during the period of March 5, 2024 to October 28, 2025.
12/14/2025, 11:23 AM • GlobeNewswire
Rosen Law Firm alerts Avantor investors about a securities class action lawsuit alleging misrepresentation of the company's competitive positioning and business prospects during the period of March 5, 2024 to October 28, 2025.
12/11/2025, 5:45 PM • GlobeNewswire
The Gross Law Firm has filed a class action lawsuit against Avantor, Inc. alleging the company issued false or misleading statements about its competitive positioning and business prospects between March 5, 2024 and October 28, 2025.
12/11/2025, 4:44 PM • GlobeNewswire
Law firm alerts shareholders about potential securities fraud class action lawsuits for multiple companies, alleging misleading statements about business performance and prospects during specific time periods.
12/10/2025, 12:00 PM • GlobeNewswire
AVTR: Kirby McInerney LLP Advises Avantor, Inc. Investors of Class Action Lawsuit
Kirby McInerney LLP is investigating a potential securities fraud class action against Avantor, alleging the company made false statements about its competitive positioning and business performance during March 5, 2024 to October 28, 2025.
12/09/2025, 6:00 PM • GlobeNewswire
Rosen Law Firm is notifying Avantor investors of a potential securities class action lawsuit alleging misrepresentation of the company's competitive positioning and business prospects during the period of March 5, 2024 to October 28, 2025.
12/05/2025, 5:30 PM • GlobeNewswire
Rosen Law Firm is notifying Avantor investors about a potential securities class action lawsuit alleging misrepresentation of the company's competitive positioning and business prospects during the period of March 5, 2024 to October 28, 2025.
12/01/2025, 2:29 PM • GlobeNewswire
Peers
Statistics
MoreInformation as of 06/22/2026
Company Profile
Avantor, Inc. engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, and fluid handling tips. It also provides equipment and instrumentation products, including filtration systems, virus inactivation systems, incubators, analytical instruments, evaporators, ultra-low-temperature freezers, biological safety cabinets, peristaltic pumps, and critical environment supplies. In addition, the company offers services and specialty procurements comprising onsite lab and production, equipment, procurement and sourcing, and biopharmaceutical material scale-up and development services. Further, it provides scientific research support services, such as DNA extraction, bioreactor servicing, clinical and biorepository, compound management, cleanroom control, monitoring, maintenance, and sanitization services. The company was founded in 1904 and is headquartered in Radnor, Pennsylvania.
Key Executives
- Corey D. Walker
- R. Brent Jones
- Emmanuel Ligner
- Michael Wondrasch
- Claudius O. Sokenu
Current Ownership Distribution
- Institutions11.5B (66.94%)
- Mutual Funds5.6B (32.42%)
- Insiders110.2M (0.64%)
- Other0 (0.00%)